Latest Breaking News On - Business development at shire pharmaceuticals - Page 1 : comparemela.com

Dyve Biosciences Appoints Camilla V. Simpson to Board of Directors Dyve Biosciences Appoints Camilla V. Simpson to Board of Directors THOUSAND OAKS, Calif., Feb. 01, 2021 Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that Camilla V. Simpson has joined Dyve’s Board of Directors. Ryan Beal, M.D., Chief Executive Officer of Dyve, stated: “We are delighted to have Camilla join our board during this exciting time for Dyve. Our lead candidate, DYV700, in Phase 2 clinical development, has shown best-in-class potential for the treatment of acute gout flares and is on track for completion of Phase 2 in the first half of this year. With DYV700 and our emerging pipeline of additional Phase 2 candidates, Camilla’s wealth of leadership experience in product strategy, portfolio management, regulatory affairs, and business development will be invaluable as we continue to build momentum. We look forward to Camilla’s immediate contribution

Camillav simpsonDyve biosciencesBryan bealPharmaceutical companyBirkbeck collegeCorporate contact jim mcgee dyve biosciences incRare strategicNational university of ireland galwayUniversity of londonDyve biosciences incBusiness development at shire pharmaceuticalsInvestor contact corey davis lifesci advisorsGlobal regulatory strategy early developmentKingston university united kingdomChief executive officerSpruce biosciences